{
  "abstract": "Background\n\nAnti-amyloid therapies lecanemab and donanemab are the first potentially disease-modifying treatments for Alzheimer's disease (AD) approved in Europe. We estimated real-world eligibility for these treatments in a large multicenter memory clinic patient cohort in Sweden (MemClin).Methods\n\nMemClin included patients with a first diagnostic visit between 2016 and 2022 at seven specialist memory clinics in Stockholm, Sweden. To estimate eligibility for anti-amyloid therapy, we applied key inclusion/exclusion criteria from the lecanemab and donanemab appropriate use recommendations. Eligible patients were required to have (1) a clinical diagnosis of AD-type dementia or mild cognitive impairment (MCI), (2) confirmed Aβ pathology (abnormal CSF Aβ42) and (3) no apparent medical exclusion criteria. Eligibility was calculated for different scenarios to provide both upper-bound estimates (main analysis) and more conservative, implementation-ready estimates of near-term treatable patients (sensitivity analysis).Results\n\nCohort consisted of 2126 patients (mean age 77.1 ± 6.6 years; 61.8% MCI, 24.2% dementia, 13.7% subjective cognitive impairment). In the main analysis, 11.5% of the whole cohort was estimated to be eligible for either treatment (lecanemab 10.6%, donanemab 11.5%). Most eligible patients had early-stage disease (61.9% MCI vs. 38.1% dementia) and an A + T- biomarker profile, that is, normal biomarker of tau (57.9%). Eligibility was markedly lower in sensitivity analyses (e.g., 2.7% when all patients without MRI were assumed ineligible).Conclusions\n\nEven upper-bound estimates indicate that a minority of real-world memory clinic patients may currently qualify for anti-amyloid therapy. These findings provide timely evidence to inform the ongoing debate on the implementation of anti-amyloid therapy in public healthcare.",
  "abstract_shown": true,
  "affiliations": [
    "Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.",
    "Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.",
    "Women's Health and Allied Health Professionals Theme, Karolinska University Hospital, Stockholm, Sweden.",
    "FINGERS Brain Health Institute, Stockholm, Sweden.",
    "Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.",
    "Ageing Epidemiology (AGE) Research Unit, School of Public Health, Imperial College London, London, UK.",
    "Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 10,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Anna Rosenberg",
      "orcid": "0000-0003-1456-7991"
    },
    {
      "affs": [
        0
      ],
      "name": "Anna Rennie",
      "orcid": "0000-0002-0976-8062"
    },
    {
      "affs": [
        0,
        2
      ],
      "name": "Urban Ekman",
      "orcid": "0000-0003-3926-8656"
    },
    {
      "affs": [
        0,
        3
      ],
      "name": "Makrina Daniilidou",
      "orcid": "0000-0002-5460-9802"
    },
    {
      "affs": [
        0,
        4
      ],
      "name": "Anette Hall"
    },
    {
      "affs": [
        0,
        3,
        5
      ],
      "name": "Anna Matton",
      "orcid": "0000-0002-7819-0495"
    },
    {
      "affs": [
        0,
        4,
        5
      ],
      "name": "Ari Solomon"
    },
    {
      "affs": [
        0
      ],
      "name": "Lars-Olof Wahlund"
    },
    {
      "affs": [
        0,
        1,
        5,
        6
      ],
      "name": "Miia Kivipelto"
    },
    {
      "affs": [
        0,
        5,
        6
      ],
      "name": "Eric Westman",
      "orcid": "0000-0002-3115-2977"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/0bk05t5z735yd.bib",
  "cited_by": 0,
  "doi": "10.1111/ene.70786",
  "fulltext_url": "https://europepmc.org/articles/PMC13681011",
  "id": "0bk05t5z735yd",
  "issns": [
    "1351-5101",
    "1468-1331"
  ],
  "landing_url": "https://europepmc.org/article/MED/42898005",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2737|Alzheimer's disease research and treatments"
    ]
  ],
  "openalex": "W7223045695",
  "pdf_url": "https://europepmc.org/articles/PMC13681011?pdf=render",
  "pmcid": "PMC13681011",
  "pmid": "42898005",
  "published": "2026-10-01",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/0bk05t5z735yd.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:37Z",
      "native_id": "MED:42898005",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42898005"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Alzheimer's disease research and treatments",
      "subfield": "physiology"
    }
  ],
  "title": "Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.",
  "title_text": "Real-World Patient Eligibility for Alzheimer's Disease Anti-Amyloid Therapy in Seven Swedish Memory Clinics.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:37Z",
  "url": "https://research.draconitic.com/paper/0bk05t5z735yd",
  "venue": "European journal of neurology",
  "versions": []
}